A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.

Alejandro Zulbaran-RojasHuei-Kan LinQiuling ShiLoretta A WilliamsBinsah GeorgeGuillermo Garcia-ManeroElias JabbourSusan O'BrienFarhad RavandiWilliam WierdaZeev E EstrovGautam BorthakurTapan Mahendra KadiaCharles CleelandJorge E CortesHagop M Kantarjian

Published in: Cancer medicine (2018)

Side effects related to TKIs may impact the quality of life in patients with CML-CP. Further studies should investigate factors (comorbidities, concomitant medications, dose and schedule, etc) associated with these symptoms and interventions that may improve the patients' QoL, including treatment discontinuation when safely feasible.

Keyphrases

chronic myeloid leukemia
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
risk factors
sleep quality
patient reported outcomes